Drug Profile
Research programme: orexin receptor modulators - Reset Therapeutics
Alternative Names: orexin 2 receptor agonistLatest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Reset Therapeutics
- Developer Alkermes plc; Reset Therapeutics
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Narcolepsy
Most Recent Events
- 21 Apr 2021 Preclinical trials in Narcolepsy in USA (unspecified route), prior to April 2021 (Alkermes pipeline, April 2021)
- 17 Mar 2016 Orexin receptor modulators licensed to Alkermes plc worldwide
- 07 Jan 2013 Reset Therapeutics and the National Institutes of Health (USA) form a 5-year collaborative agreement for development of a therapy for narcolepsy in USA